Navigation Links
Anthracycline in Medical News

Gene alterations associated with response to anthracycline therapy for breast cancer

Alterations in the topoisomerase II alpha ( TOP2A ) gene were associated with better patient outcomes following anthracycline-based therapy compared with non-anthracycline-based regimens, according to a study in the April 28 online issue of the Journal of the National Cancer Institute. The incre...

Longer Anthracycline Therapy Reduces Heart Failure in Adult Cancer Patients

Stretching out a dose of chemotherapy over six or more hours may reduce the risk of heart problems caused by certain commonly used cancer drugs, according to a new// review of recent research. Anthracycline drugs like daunorubicin and doxorubicin are used to treat many types of solid tumors a...

Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe

...s later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. It also can be...

Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer

... with locally advanced and metastatic breast cancer who have received prior anthracycline treatment have special treatment challenges, and Centocor Ortho Biotech Pro...ngestive heart failure or cardiomyopathy may occur after discontinuation of anthracycline therapy For patients with a history of cardiovascular disease, o...

Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review

...s later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. It also can be...

Pixantrone Now Available in Europe on a Named-Patient Basis

...s later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. Pixantrone has...

Drug May Help Against Inflammatory Breast Cancer

...fluid under the skin of more than two-thirds of the breast, tenderness, hardening and warming of the breast. For patients resistant to conventional anthracycline or taxane and trastuzumab, treatment options are limited. Lapatinib inhibits HER2, a protein that's expressed much more in inflammatory breast cancer ...

Cell Therapeutics Initiating Rolling NDA Submission for Pixantrone

...s later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. Pixantrone has...

CTI Focuses on Late-Stage Drug Approvals and Commercialization and Cuts Operating Costs: to Close Bresso Research Center

...ontains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pi...ontains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. Anthracyclines have been shown to be very active clin...

How chemotherapy drugs block blood vessel growth, slow cancer spread

...ight particularly benefit from these drugs. The anthracycline class of chemotherapeutics doxorubicin (Adriamyci... than 99 percent. They tested other members of the anthracycline drug class and found that doxorubicin, epirubicin ... by HIF-1 in untreated cells were found unbound in anthracycline treated cells. "We know that this class of drug pr...
Anthracycline in Medical Technology

Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th

...s later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. It also can be...

Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL

...nding to topoisomerase II enzyme, a key target for anthracycline mediated tumor death. These modifications are also...eclinical animal studies when compared to standard anthracycline drugs. Five phase I/II studies in which pixan...s later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been t...

Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment

...aggressive non-Hodgkin's lymphoma ("NHL") for whom anthracycline and related drugs are typically not to be used due...re of these patients, most of whom had received an anthracycline as part of a salvage regimen, was 386 mg/m2 (with ... doxorubicin, but even in patients who received an anthracycline as part of a salvage regimen. Resistance to ritux...

Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting

...s later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. Pixantrone has...

Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma

...ity," noted Jack Singer, M.D., Chief Medical Officer at CTI. "The rapid time-to-response data coupled with the relatively low incidence of traditional anthracycline toxicities and a safety profile that compares favorably to standard chemotherapy, positions pixantrone to live up to the promise of providing patients...

Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone

...ontains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pix...ontains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. Anthracyclines have been shown to be very active clini...

Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer

... breast cancer who were treated previously with an anthracycline in the adjuvant setting experienced a significant ...east cancer who have relapsed after prior adjuvant anthracycline therapy." Study Background The stu...athy may occur after discontinuation of anthracycline therapy - For patients with a history of ...

Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint

...antrone Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pixantrone is a novel DNA major groove binder that contains an aza-anthracened...

Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial

...antrone Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pixantrone is a novel DNA major groove binder that contains an aza-anthracened...

EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting

...m/cgi-bin/prnh/20010620/ENMDLOGO ) For this Phase 2 single agent, open label study, a total of 65 patients who had previously received at least one anthracycline and taxane therapy were enrolled. 55 patients were evaluable for tumor response. Of the evaluable patients, the antitumor activity observed with MKC-1...
Anthracycline in Biological News

Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer

... Berlin, Germany: Women with a particularly aggressive form of breast cancer seem to do better if they are treated with a combined anthracycline and taxane chemotherapy regimen before surgery, together with trastuzumab (Herceptin) before and after surgery, according to results from the largest ...

Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors

...treatments from our results so far, but it does seem that the higher sensitivity to treatment by BRCA2-associated patients is especially caused by the anthracycline regimen. The project leader, Professor Jan Klijn, medical oncologist and chairman of the Rotterdam Family Cancer Clinic, said: Our findings show th...

A search for protection against chemotherapy cardiotoxicity

... Biology and Medicine. Although rare, cardiotoxicity is a serious complication of cancer treatment. Indeed, the use of chemotherapeutic agents such as anthracycline or trastuzumab in oncology is limited by their cardiac toxicity. Therefore, it is of interest to identify new protective agents preventing these adver...
Anthracycline in Biological Technology

Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

...ug in such patients and deserves to be examined in anthracycline naive patients as a potential alternative to currently available standard anthracycline drugs." The PIX 301 EXTEND ( E xpanding the...s later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been t...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... Cardiac function should be carefully monitored Congestive heart failure or cardiomyopathy may occur after discontinuation of anthracycline therapy For patients with a history of cardiovascular disease, or if the results of cardiac monitoring indicate possible cardiac injury, ...

Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial

...s later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. Pixantrone has...

Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients

...reatment-related symptomatic congestive heart failure. This is noteworthy because cardiotoxicity is a common and therapy-limiting adverse event of the anthracycline class of anti-cancer agents and because Herceptin(R) has its own, well recognized, potential for cardiac toxicity. Myocet is a liposomal delivery...

Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer

...hosphamide Improved Overall Survival Versus An anthracycline Combination SAN ANTONIO, Dec. 13 /PRNewswire-Fir...Oncology, helped develop the regimen combining the anthracycline doxorubicin with cyclophosphamide, which became a ...signs of cancer at seven years, as compared to the anthracycline combination," said Dr. Jones. US Oncology Adjuva...

FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML

...congenital long QT syndrome and patients taking anti- arrhythmic drugs, other medicinal products that lead to QT prolongation, or cumulative high-dose anthracycline therapy. Hypokalemia or hypomagnesemia should be corrected prior to SPRYCEL administration. Drug Interactions: Dasatinib is a CYP3A4 substrate. Drug...

FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer

...ine, and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. IXEMPRA is a microtubule inhibitor belonging to...nes, and whose tumors had demonstrated prior resistance to these therapies. anthracycline resistance is defined as progression while on therapy or within six months ...

Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission

... treatment of various hematological malignancies, solid tumors and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associ...
Anthracycline in Biological Dictionary

Intercalation

...as to investigate whether hydrotalcite is able to intercalate diclofenac, a nonsteroidal anti-inflammatory drug, and release it in a ... Anticancer anthracycline - DNA complex by intercalation ... As a result of intercalation with daunomycin4, the GC and CG base pairs 'buckle' by ca. ... Information ab...
Other Tags
(Date:8/20/2014)... In a recent article published by the ... (UCL) study showed that dental experts from around the ... was the most effective. Analysis of 66 different advice ... frequently recommended, but none were favored by a majority. ... experienced cosmetic dentist Dr. Patrick J. Broome, DMD, ...
(Date:8/20/2014)... NY (PRWEB) August 20, 2014 ... consecutive year on its 33rd annual Inc. 500|5000, ... companies. The list represents the most comprehensive look ... independent entrepreneurs. Companies such as Yelp, Pandora, Timberland, ... well-known names gained early exposure as members of ...
(Date:8/20/2014)... August 20, 2014 BuyCheapTicketsToEvents.com is ... wide selection of tickets to many events. Cheap NHL hockey ... begin in September. , Hockey fans are enthusiastic about their ... tickets for games. Now is the time to acquire 2014 ... in mere months. There will be a great deal of ...
(Date:8/20/2014)... 20, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Sodium Chloride IV . ... lot of Sodium Chloride IV 0.9%, USP 1000 mL, by ... presence of particulate matter. Sodium Chloride Injection, USP is used ... priming solution in hemodialysis procedures. , The reason ...
(Date:8/20/2014)... Kowa Optimed returns after a short hiatus ... new SL-17 portable slit lamp. , The SL-17 has ... controlled by an illuminated thumb wheel for easy adjustments ... available AAA rechargeable and dry cell batteries, which is ... designed specifically for the device. The new Sl-17 base ...
Breaking Medicine News(10 mins):Health News:Ending Confusion About the Best Way to Brush Teeth 2Health News:Ending Confusion About the Best Way to Brush Teeth 3Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 2Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 3Health News:2014 NHL Preseason Tickets Are Among Top Selling Seats at Trusted Provider BuyCheapTicketsToEvents.com 2Health News:Sodium Chloride IV 0.9% by Baxter Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2
(Date:8/19/2014)... news release is available in German . ... get new information about the metabolism of plants can ... However, Erich Kombrink from the Max Planck Institute for ... the University of Duisburg-Essen adopt a different approach. They ... metabolic process like brake pads and prevent the downstream ...
(Date:8/19/2014)... Daylight was breaking over the central Pacific and ... about a dozen scientists strategized for the day ahead. ... to collect water samples around the southern Line Islands, ... gizmos and delicate machinery strewn throughout the 158-foot research ... research group to bring a DNA sequencer out into ...
(Date:8/18/2014)... , August 19, 2014 ... Ready biometric authentication in smart devices  ... (TEEs) for smart devices, and Fingerprint Cards AB ... availability of FIDO Ready™ secure biometric authentication on ... FPCs touch fingerprint sensors (FPC1020, FPC1021 and FPC1150) ...
Breaking Biology News(10 mins):Researchers block plant hormone 2Researchers block plant hormone 3Sequencing at sea 2Sequencing at sea 3Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 2Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 3Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 4
Other Contents